ASLAN PHARMACEUTICALS ADR REP 5’s (ASLN) Buy Rating Reaffirmed at HC Wainwright
“Our price target is derived from a market value of the firm at $382M. This valuation includes a discounted cash flow analysis based asset value of $392M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate and excluding $10M debt.”,” HC Wainwright’s analyst wrote.
Separately, Zacks Investment Research upgraded ASLAN PHARMACEUTICALS ADR REP 5 from a sell rating to a hold rating in a research report on Friday, November 2nd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has an average rating of Buy and an average price target of $10.94.
ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.27. On average, equities research analysts expect that ASLAN PHARMACEUTICALS ADR REP 5 will post -1.41 EPS for the current year.
A number of hedge funds have recently modified their holdings of the stock. MYDA Advisors LLC acquired a new position in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter worth approximately $195,000. Platinum Investment Management Ltd. acquired a new position in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter worth approximately $2,532,000. Finally, Temasek Holdings Private Ltd acquired a new position in ASLAN PHARMACEUTICALS ADR REP 5 during the 2nd quarter worth approximately $12,660,000. Hedge funds and other institutional investors own 10.87% of the company’s stock.
About ASLAN PHARMACEUTICALS ADR REP 5
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China.
Read More: Earnings Per Share
Receive News & Ratings for ASLAN PHARMACEUTICALS ADR REP 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEUTICALS ADR REP 5 and related companies with MarketBeat.com's FREE daily email newsletter.